Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Leukemia

Free Subscription 06.04.2026 1 Acta Haematol 1 Am J Hematol 3 Ann Hematol 2 Blood 1 BMC Cancer 1 Cancer 1 Cancer Res 1 Cell 1 Eur J Haematol 3 Int J Hematol 2 J Clin Oncol 5 J Pediatr Hematol Oncol 4 Leuk Lymphoma 2 Leuk Res 5 Leukemia 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Haematol

1. GOULART H, Braish J, Short NJ, Jain N, et al
   A Case Report of Tyrosine Kinase Inhibitor Interruption in a Patient with Multilineage Philadelphia Positive Acute Lymphoblastic Leukemia.
   Acta Haematol. 2026 Mar 31:1-8. doi: 10.1159/000551699.
   PubMed         Abstract available
   
   

   
   Am J Hematol

2. PICCINI M, Gangat N, Mannelli F, Scappini B, et al
   Clinical Experience With Venetoclax-Based Combinations for Relapsed/Refractory or MRD-Positive NPM1-Mutated Acute Myeloid Leukemia.
   Am J Hematol. 2026 Apr 1. doi: 10.1002/ajh.70313.
   PubMed        
   
   

   
   Ann Hematol

3. DEREME J, Segot A, Nabergoj M, Dewarrat N, et al
   Correspondance: Venetoclax combined with FLAG-based chemotherapy induces rapid and deep responses in early T-cell precursor lymphoblastic leukemia/lymphoma. Report of two cases and review of the literature.
   Ann Hematol. 2026;105:223.
   PubMed        
   
   
4. NEGISHI S, Miyao K, Ohara F, Motegi K, et al
   Letermovir improves the outcome of allogenic stem cell transplantation with anti-thymocyte globulin against acute leukemia and myelodysplastic syndromes.
   Ann Hematol. 2026;105:224.
   PubMed         Abstract available
   
   
5. ZHAO L, Yao H, Ji Y, Zhu Y, et al
   Epidemiological trends and burden projections of childhood leukemia in China: age-stratified analysis and impact of COVID-19 from 1990 to 2035.
   Ann Hematol. 2026;105:216.
   PubMed         Abstract available
   
   

   
   Blood

6. TSVETNOV IV, Lyapichev KA
   Breast hairy cell leukemia mimicking lobular breast carcinoma.
   Blood. 2026;147:1648.
   PubMed        
   
   
7. ZWAAN CM, Tasian SK, Aplenc R, Brodersen LE, et al
   Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel.
   Blood. 2026;147:1532-1561.
   PubMed         Abstract available
   
   

   
   BMC Cancer

8. AHMAD H, Henna F, Khurram S, Khan A, et al
   Efficacy and safety of ATRA plus arsenic trioxide versus ATRA plus chemotherapy in newly diagnosed acute promyelocytic leukemia: a grade-assessed systematic review and meta-analysis.
   BMC Cancer. 2026 Mar 29. doi: 10.1186/s12885-026-15932.
   PubMed        
   
   

   
   Cancer

9. PERRONE S, De Fazio L, Monachetti S, Molica M, et al
   Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta-analysis of a shifting treatment paradigm.
   Cancer. 2026;132:e70372.
   PubMed         Abstract available
   
   

   
   Cancer Res

10. LAU BK, Haarer EL, Ahn JH, Wang GG, et al
    A Unified Model: Chromatin-Bound Multicomponent Condensates.
    Cancer Res. 2026;86:1543-1544.
    PubMed         Abstract available
    
    

    
    Cell

11. LI F, Hu Y, Wang Y, Zhang X, et al
    Ferritin aggregation cell engager for CAR T avidity engineering against refractory leukemias.
    Cell. 2026;189:1942-1956.
    PubMed         Abstract available
    
    

    
    Eur J Haematol

12. BRUZZESE A, Vigna E, Martino EA, Caserta S, et al
    Targeting the Menin-KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation.
    Eur J Haematol. 2026 Apr 2. doi: 10.1111/ejh.70186.
    PubMed         Abstract available
    
    

    
    Int J Hematol

13. YAMAGUCHI K, Aoki M, Osako R
    Postmarketing surveillance study of asciminib in patients with resistant/intolerant chronic myeloid leukemia in Japan.
    Int J Hematol. 2026 Mar 31. doi: 10.1007/s12185-026-04199.
    PubMed         Abstract available
    
    
14. OGASAWARA F, Minami Y, Chi S, Ueda T, et al
    Clinical significance of TP53 mutations in patients with acute myeloid leukemia: the HM-SCREEN-JAPAN 01/02 study.
    Int J Hematol. 2026 Mar 31. doi: 10.1007/s12185-026-04192.
    PubMed         Abstract available
    
    
15. IZUMI A, Tachibana T, Miyazaki T, Takeda T, et al
    Safety and efficacy of clofarabine for preconditioning intervention in patients undergoing allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphoblastic leukemia.
    Int J Hematol. 2026 Mar 31. doi: 10.1007/s12185-026-04201.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

16. LANINO L, Hunter AM, Gagelmann N, Robin M, et al
    Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia.
    J Clin Oncol. 2026 Mar 27:JCO2502116. doi: 10.1200/JCO-25-02116.
    PubMed         Abstract available
    
    
17. PEMMARAJU N, Marconi G, Montesinos P, Lane AA, et al
    Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.
    J Clin Oncol. 2026;44:861-873.
    PubMed         Abstract available
    
    

    
    J Pediatr Hematol Oncol

18. KOBAYASHI R, Hori D, Sano H, Matsushima S, et al
    Invasive Fungal Infection in Patients With Initial Treatment of Pediatric Acute Lymphoblastic Leukemia: A Single-Center Study in Japan.
    J Pediatr Hematol Oncol. 2026 Mar 19. doi: 10.1097/MPH.0000000000003191.
    PubMed         Abstract available
    
    
19. UZEL VH
    Complete Urinalysis and Urine Culture Results in Children With Febrile Neutropenic Leukemia.
    J Pediatr Hematol Oncol. 2026 Mar 20. doi: 10.1097/MPH.0000000000003188.
    PubMed         Abstract available
    
    
20. HASAN EMA, Elsherif NHK
    Clinical Characteristics and Outcome of Leukemia and Malignant Solid Tumors Among Infant Age Group: A 15-Year Study in a Tertiary Care Hospital in Egypt.
    J Pediatr Hematol Oncol. 2026 Mar 25. doi: 10.1097/MPH.0000000000003190.
    PubMed         Abstract available
    
    
21. YI I, Foley M, Flagg A, Massaro S, et al
    Two Cases of Severe Cytomegalovirus Disease in Nontransplant Pediatric Acute Lymphoblastic Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
    J Pediatr Hematol Oncol. 2026 Mar 20. doi: 10.1097/MPH.0000000000003193.
    PubMed         Abstract available
    
    
22. KARACHUNSKIY AI, Kovalenko SG, Lebedev VV, Plaksina OI, et al
    Phase 2, Multicenter Studies of Pegaspargase in Pediatric Patients With Previously Untreated Acute Lymphoblastic Leukemia in Russia: Comparative Study of Liquid and Lyophilized Pegaspargase and Roll-Over Study of Lyophilized Formulation.
    J Pediatr Hematol Oncol. 2026 Apr 3. doi: 10.1097/MPH.0000000000003176.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

23. NAKAMURA D, Ueno T, Nakabeppu SI, Shyodai A, et al
    Validation of prognostic indices in adult T-cell leukemia/lymphoma and their prognostic value at the start of second-line treatment.
    Leuk Lymphoma. 2026 Apr 1:1-7. doi: 10.1080/10428194.2026.2645946.
    PubMed         Abstract available
    
    
24. CRODEN J, Garcia-Manero G, Chien K, DiNardo C, et al
    A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2026 Mar 30:1-7. doi: 10.1080/10428194.2026.2650674.
    PubMed         Abstract available
    
    
25. MERRILL M, Kim HT, Kelkar AH, Panaro K, et al
    Allogeneic transplant outcomes in T-cell prolymphocytic leukemia: a single-center retrospective study.
    Leuk Lymphoma. 2026 Mar 30:1-7. doi: 10.1080/10428194.2026.2645933.
    PubMed         Abstract available
    
    
26. PUSTAKE M, Odeh J, Harisingani A, Khosla A, et al
    Temporal improvements in survival with persistent disparities in acute myeloid leukemia: a two-decade population-based analysis from the United States.
    Leuk Lymphoma. 2026 Mar 30:1-14. doi: 10.1080/10428194.2026.2643750.
    PubMed         Abstract available
    
    

    
    Leuk Res

27. HU X, Zhu H, Li C
    Discovery of METTL3 inhibitor C191-0266 as a leukemia therapeutic through targeted modulation of protective autophagy.
    Leuk Res. 2026;165:108167.
    PubMed         Abstract available
    
    
28. CARRAWAY HE, DeAngelo DJ, Wang ES, Komrokji RS, et al
    Clinical strategies for leukemia management: Recommendations from the Bridging the Gaps in Hematology Oncology Consensus Conference 2025.
    Leuk Res. 2026;164:108203.
    PubMed         Abstract available
    
    

    
    Leukemia

29. TIAN Z, Gao P, Zhang Y, Ma J, et al
    PRMT1 facilitates the tumorigenesis of chronic lymphocytic leukemia by regulating methylation of MAST1.
    Leukemia. 2026 Mar 30. doi: 10.1038/s41375-026-02935.
    PubMed         Abstract available
    
    
30. PARK J, Kim SH, Park J, Park H, et al
    BCR::ABL1 tyrosine kinase inhibitors induce ribosome collisions to activate ZAK-dependent ribotoxic stress and apoptosis in chronic myeloid leukemia.
    Leukemia. 2026 Mar 30. doi: 10.1038/s41375-026-02916.
    PubMed         Abstract available
    
    
31. PERUSINI MA, Pagnano K, Pavlovsky C, Zackova D, et al
    The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
    Leukemia. 2026 Mar 30. doi: 10.1038/s41375-026-02921.
    PubMed        
    
    
32. KIRCHHOFF H, Schoenherr C, Fleischer L, Talbot SR, et al
    Differential mitochondrial priming by BCR::ABL1 in B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2026 Mar 30. doi: 10.1038/s41375-026-02944.
    PubMed        
    
    
33. GAGNON LL, Duminuco A, Stagno F, Sobas M, et al
    Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes.
    Leukemia. 2026 Mar 27. doi: 10.1038/s41375-026-02928.
    PubMed         Abstract available
    
    

    
    PLoS One

34. QIU R, Zhou Y, Song S, Wang Z, et al
    GSK3beta as a potential regulator in AML: A pan-cancer multi-omics analysis.
    PLoS One. 2026;21:e0344994.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum